Skip to content

Exact Sciences Revenues Skyrocket

Exact Sciences’ fourth quarter results are beating market expectations. Total revenue for the quarter is expected to be just under $300 million. Approximately 1.68 million Cologuard tests were completed in 2019, an 80% year-over-year increase. Analysts are bullish on the company’s stock and expect Exact Sciences to grow 40% in 2020.

Back To Top